19 January 2023



The Nifty ended 0.32% down at 18107.85. It opened on a flat note and remained range-bound throughout the session towards ending on a subdued note. Failing to close above 18150 suggesting it may continue range-bound oscillation. However, staying cautious on rise is advised. Chart pattern suggesting intraday range likely to be 18000-18250. Midway resistance is placed around 18150 levels.

On the Nifty hourly chart, the Benchmark Index is still seen hovering around the critical MA band. Hence, staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; the Benchmark Index may find sellers on rise in the resistance zone placed around 18200-18250. Index majors may find sellers on rise around critical resistances.

Nifty Crucial Supports & Resistances-Supports- 18000, 17800 Resistances- 18200, 18250

Open Positional Calls-

T+30 INST POSITIONAL SELL-

|Fut Segment| BANK OF BARODA @ 185-190, TGT- 150, Closing SL- above 210

T+30 INST POSITIONAL SELL-

|Fut Segment| SBIN @ 620-625, TGT- 575, Closing SL-above 650 $\,$

T+30 INST POSITIONAL SELL-

|Fut Segment| ITC @ 335-340, TGT- 305, Closing SL- above 355 $\,$

T+30 INST POSITIONAL SELL-

|Fut Segment| CAN BANK @ 330-335, TGT- 295, Closing SL - above 355

T+30 INST POSITIONAL SELL-

 $| {\it Fut Segment}| \ {\it RBL BANK @ 182-184, TGT-154, Closing SL-above 199}$

T+15 INST POSITIONAL SELL-

|Fut Segment| AMBUJA @ 535-540, TGT- 490, Closing SLabove 565

T+15 INST POSITIONAL SELL-

|Fut Segment| HIND PETRO @ 250-255, TGT- 235, Closing SL- above 265

T+5 BLIY-

|Cash Segment| TECH MAHINDRA @ 1045-1040, TGT-1080, Closing SL- below 1020

Key Contents	Page No.
Result Update	4
Domestic News	7







Market in Retrospect

The Indian benchmark indices snapped their two-day rally to close lower in trade on Thursday.

Nifty index ended 0.32% lower, ended at 18,108. The broader markets represented by the Nifty 500 Index ended 0.30% lower, ending at 15,420. Among the sectorial indices, Nifty PSE was the top gainer gaining by 0.70%, followed by Nifty PSU Bank was gaining by 0.33%. Nifty Media was the top losser losing by 1%.

Coal India was the top gainer, gaining by 3.27%, followed by UPL and ONGC which gaining by 2.08% & 1.67%. Adami Enterprises was the top loser, losing by 3.70%, followed by Asian Paints and Tata Motors which losing by 2.69% & 1.87%.

Market Turnover (In Crore) 19-01-2023							
Name		Last		Previous			
NSE Cash		41568.77		45891.73			
NSE F&O	324	144587.02		16907212.07			
BSE Cash		2,992.50		2,720.07			
BSE F&O		*NA		90.62			
FII Derivatives Flow (In Crore) 18-01-2023*							
Instrument	Purchase		Sale	Net			
Index Future	3948.95	202	22.12	1926.83			
Index Option	911258.74	91835	50.99	7092.25			
Stock Future	12671.47	1193	36.27	735.2			
Stock Option	12597.69	1268	31.12	83.43			
Institutional Flow (In Crore) 19-01-2023							
Institution	Purchase		Sale	Net			
FII	7780.87	738	80.89	399.98			
DII	4321.53	445	50.49	128.96			

NIFTY Top Ga	iners					
Name	%1D	%5D	Day Vol	Avg 5 Day Vol		
Coal India	3.27	4.70	12938871	5426702		
UPL	2.08	4.14	3553403	1288710		
ONGC	1.67	3.83	18437610	12489090		
BPCL	1.04	1.33	1639556	2457282		
SBI Life Insurance	0.95	0.56	1189082	1033642		
NIFTY Top Los	ers					
Name	%1D	%5D	Day Vol	Avg 5 Day Vol		
Kotak Bank	1.77	0.69	4425644	2919718		
Indusind Bank	1.84	0.71	9691261	2022913		
Tata Motors	1.87	2.79	13126520	12007820		
Asian Paints	2.69	1.71	2379947	1064171		
Adani Enterprises	3.70	5.04	3696319	1949793		
Bulk and Block Deals						


https://www.nseindia.com/products/content/equities/equities/bulk.htm http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx

^{*}Data not updated till 9:25PM





Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	60858.43	187.31	0.31	1.50	1.53	2.96	1.26
Nifty	18107.85	57.50	0.32	1.40	1.70	3.40	0.94
BSE M Cap	25171.93	13.91	0.06	0.10	2.86	0.41	1.22
BSE S Cap	28773.27	68.36	0.24	0.08	2.80	0.11	5.82
Nifty MC 100	31344.60	34.70	0.11	0.05	2.62	1.16	0.06
BSE Auto	29260.00	142.95	0.49	0.10	1.71	0.33	10.97
BSE Capgoods	35138.99	77.53	0.22	2.87	0.98	8.90	14.99
BSE FMCG	16109.98	135.08	0.83	0.80	3.61	0.36	17.56
BSE Metal	21916.96	124.89	0.57	3.15	6.24	18.73	8.86
BSE Oil&Gas	20934.17	163.28	0.79	2.07	1.48	14.13	10.36
BSE Healthcare	23030.97	85.54	0.37	0.20	0.27	1.59	8.11
BSE Power	4498.65	46.43	1.02	2.63	0.92	4.11	14.40
BSE Realty	3434.96	4.03	0.12	1.20	2.66	0.99	13.70
BSE ConsDur	38330.11	308.06	0.80	1.61	4.29	8.86	15.92
BSE Bank	48044.65	168.85	0.35	0.31	2.68	4.05	10.53
BSE IT	29604.73	1.33	0.00	3.12	3.39	4.64	20.29

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.36	0.01	0.17	2.20	6.15	18.61	80.42
UK	3.29	0.03	0.79	1.38	6.11	15.21	161.78
Brazil	6.16	0.39	6.72	5.48	3.10	8.49	23.71
Japan	0.44	0.02	3.92	13.53	72.94	71.60	206.25
Australia	3.32	0.22	6.32	7.62	5.97	15.79	66.35
India	7.31	0.01	0.15	0.18	0.22	1.83	10.80
Switzerland	1.08	0.03	2.56	6.89	17.91	17.47	1798.25
Germany	2.05	0.03	1.34	5.05	6.95	13.72	17183.3

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	81.36	0.12	0.14	0.24	1.65	2.00	8.52
USD Index	102.21	0.15	0.15	0.95	2.40	9.54	7.01
YUAN	6.79	0.03	0.43	0.85	2.84	6.50	6.51
GBP	1.23	0.00	0.17	0.96	1.47	9.88	9.44
EUR	1.08	0.00	0.27	0.28	2.04	10.74	4.58
YEN	128.54	0.36	0.28	0.55	6.51	16.62	11.05

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	874.00	47.00	5.10	16.20	43.54	53.29	44.33
Baltic Dirty	1421.00	6.00	0.42	1.39	30.45	16.90	105.35
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33296.96	613.89	1.81	1.21	1.65	9.44	4.94
Nasdaq	10957.01	138.10	1.24	2.00	3.90	2.59	23.59
S&P 500	3928.86	62.11	1.56	0.25	2.91	6.32	13.32
FTSE100	7767.13	60.65	0.77	0.31	5.55	12.20	2.38
CAC40	6995.76	83.54	1.18	0.35	8.13	15.88	2.41
DAX	14999.16	176.37	1.16	0.35	7.62	17.77	5.09
Mexico IPC	53218.83	89.87	0.17	0.02	6.55	15.15	0.75
Brazil Bovespa	112228.4	789.27	0.71	0.26	7.15	3.48	3.90
Russian RTS	994.28	11.84	1.18	2.11	0.32	1.56	29.70
Japan Nikkei	26405.23	385.89	1.44	0.17	3.06	3.13	3.87
Hang Seng	21650.98	27.02	0.12	0.64	11.88	31.13	10.27
Taiwan Index	14932.93	5.92	0.04	0.88	2.78	13.78	18.75
Shanghai Comp	3240.28	15.87	0.49	2.43	4.29	6.43	8.93
KOSPI	2380.34	12.02	0.51	0.64	1.20	6.39	16.25
Malaysia KLCI	1496.22	0.72	0.05	0.51	1.30	5.73	2.23
Jakarta Comp	6819.91	54.12	0.80	2.87	0.59	0.59	3.46
Philippine SE	7062.01	32.85	0.46	3.34	10.10	14.86	2.75
Thai Exch	1688.48	3.04	0.18	0.06	4.34	6.28	1.82

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	78.56	0.89	1.12	1.52	4.52	8.14	9.63
BRENT Crude	84.20	0.77	0.91	0.21	5.08	3.67	6.16
Natural Gas	3.32	0.02	0.45	9.40	41.75	44.71	21.46

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1908.61	3.63	0.19	0.56	6.72	17.08	3.65
Silver(\$/Ounce)	23.40	0.08	0.33	1.64	1.74	26.67	3.11
Aluminium	2611.70	17.95	0.69	5.41	11.75	19.72	13.76
Copper	9326.00	43.01	0.46	2.40	13.26	24.63	3.71
Zinc	3422.96	110.21	3.33	6.10	12.28	18.88	4.37
Lead	2188.26	50.74	2.27	0.71	1.53	6.77	5.85

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	155.75	0.75	0.48	8.23	5.20	16.82	34.97
Cotton	84.71	0.10	0.12	0.53	0.75	8.64	11.65
Sugar	19.84	0.02	0.10	0.97	1.49	6.38	7.53
Wheat	740.75	1.75	0.24	0.10	1.04	13.82	6.65
Soybean	1522.25	2.25	0.15	1.96	4.01	9.38	17.68



HUL

India's largest fast-moving consumer goods company Hindustan Unilever Ltd reported standalone net profit for the third quarter ended December 2022 rose 11.6% year-on-year (YoY) to INR2,505 crore, helped by an increasing demand for its beauty and personal care products, which offset a rise in raw-material costs. The firm had reported a profit of INR2,243 crore in the corresponding quarter of last year. The profit was higher than the average profit forecast of INR2,497.90 crore. The Indian arm of global consumer goods giant Unilever Plc recorded double-digit revenue growth of 16% at INR14,986 crore for the third quarter of the financial year 2022-23 as against INR12,900 crore in the year-ago period. This revenue growth was largely driven by Beauty and Personal Care Segment, Home Care, and price hikes in laundry. Growth was ahead of the market with more than 75% of the business winning market shares. The firm has reported an EBITDA or earnings before interest, tax, depreciation, and amortization of INR3,537 crore in the December quarter. Meanwhile, the company's EBITDA margins dipped 180 bps YoY to 23.6%.

Asian Paints

Asian Paints consolidated net profit for the December quarter rose 5.6% on year to Rs 1,073 crore, while revenue increased by a moderate 1.3% to Rs 8,636.74 crore. Consolidated operating profit increased by 4.5% on year to Rs 1,611.43 crore, while margin expanded 57 basis points to 18.66%. The domestic decorative business saw flat growth both in volume and value terms in the quarter, as the base quarter of last year saw a high increase in prices. International sales increased 2.1% in the quarter to Rs 778.82 crore. In constant currency terms, sales increased by 13.4%.

AU Small Finance Bank

Net profit of AU Small Finance Bank rose 30.05% to Rs 392.83 crore in the quarter ended December 2022 as against Rs 302.05 crore during the previous quarter ended December 2021. Total Operating Income rose 41.54% to Rs 2118.07 crore in the quarter ended December 2022 as against Rs 1496.45 crore during the previous quarter ended December 2021.

Havells India

Net profit of Havells India declined 7.29% to Rs 283.52 crore in the quarter ended December 2022 as against Rs 305.82 crore during the previous quarter ended December 2021. Sales rose 12.65% to Rs 4127.67 crore in the quarter ended December 2022 as against Rs 3664.21 crore during the previous quarter ended December 2021.

L&T Tech Services

L&T Technology Services reported a 22 per cent rise in net profit to INR303.6 crore for the December 2022 quarter. This is against a net profit of INR248.8 crore in the year-ago period. The revenue of the company grew by 21.4 per cent to INR2,048.6 crore in the quarter under review from INR1,687.5 crore a year ago. EBIT for the quarter stood INR382.9 crore while the EBIT margin at 18.7 per cent.



Hindustan Zinc

Hindustan Zinc, a subsidiary of Vedanta, reported a consolidated net profit of INR2,156 crore for the December quarter, which is 20% lower than INR2,701 crore reported in the year-ago period. On a sequential basis, the profit after tax (PAT) declined 19%. It was INR2,680 crore in the September quarter (Q2FY23). Revenue from operations, meanwhile, declined 2% to INR7,628 crore as against INR7,841 crore in the same quarter last year. The company's EBITDA came in at INR3,717 crore in the three months period, down 15% year-on-year from INR4,392 crore. The mining company has declared a third interim dividend of INR13 per share, amounting to INR5,493 crore.

ICICI Securities

Net profit of ICICI Securities declined 26.13% to Rs 280.95 crore in the quarter ended December 2022 as against Rs 380.35 crore during the previous quarter ended December 2021. Sales declined 6.66% to Rs 878.96 crore in the quarter ended December 2022 as against Rs 941.64 crore during the previous quarter ended December 2021.

Happiest Minds

Happiest Minds Technologies garnered a consolidated net profit of INR57.58 crore in the December 2022 quarter (Q3FY23) period. The latest PAT climbed by 17.70% from a profit of INR48.92 crore recorded in Q3FY22, while it was up by 3.1% from the INR59.41 crore profit witnessed in Q2 of FY23. Consolidated revenue from contracts with customers stood at INR366.88 crore increasing by 29.21% from INR283.94 crore in the third quarter of last year. However, revenue surged by 3.2% from INR355.51 crore in September 2022 quarter. During the quarter under review, EBIT came at INR79.5 crore, while margins were at 21.7%. Overall, total income on a consolidated basis stood at INR374.68 crore in Q3FY233 versus INR292.28 crore in Q3FY22 and INR359.33 crore in Q2FY23. On a standalone basis, Q3FY23 PAT came in at INR57.27 crore versus INR44.78 crore in Q3FY22 and INR55.31 crore in Q2FY23. Revenue stood at INR344.76 crore in Q3FY23 versus INR265.88 crore in Q3FY22 and INR337.65 crore in Q2 of FY23.

Datamatics Global Services

Net profit of Datamatics Global Services rose 24.07% to Rs 45.87 crore in the quarter ended December 2022 as against Rs 36.97 crore during the previous quarter ended December 2021. Sales rose 23.90% to Rs 372.64 crore in the quarter ended December 2022 as against Rs 300.77 crore during the previous quarter ended December 2021.

Kuantum Papers

Net profit of Kuantum Papers rose 1317.82% to Rs 57.28 crore in the quarter ended December 2022 as against Rs 4.04 crore during the previous quarter ended December 2021. Sales rose 52.18% to Rs 348.51 crore in the quarter ended December 2022 as against Rs 229.01 crore during the previous quarter ended December 2021.



PVR

PVR, the largest multiplex chain in the country, posted a consolidated net profit of Rs 16.1 crore during October-December 2022 quarter, against a loss of Rs 10 crore in the year-ago period. Revenue from operations rose 53 percent year-on-year (YoY) to Rs 941 crore from Rs 614 crore registered in the corresponding quarter of the previous fiscal. EBITDA (earnings before interest, taxes, depreciation and amortisation) grew 75.1 percent YoY to Rs 288.8 crore. Margins also improved YoY from 26.9 percent to 30.7 percent. During the last year, PVR has opened 63 screens across 11 cinemas till date and is on track to open a total of 100-110 new screens by the end of the current fiscal year.

Sterling & Wilson Renewable Energy

Net Loss of Sterling & Wilson Renewable Energy reported to Rs 101.24 crore in the quarter ended December 2022 as against net loss of Rs 422.41 crore during the previous quarter ended December 2021. Sales declined 72.78% to Rs 406.96 crore in the quarter ended December 2022 as against Rs 1494.86 crore during the previous quarter ended December 2021.



Alembic Pharmaceuticals gets USFDA nod to market generic cancer drug

Alembic Pharmaceuticals has received approval from the US health regulator to market Acalabrutinib Capsules, used in the treatment of mantle cell lymphoma, in the American market. The company has received tentative approval from the US Food & Drug Administration (USFDA) for Acalabrutinib Capsules (100 mg). The company's product is therapeutically equivalent to AstraZeneca UK's Calquence Capsules (100 mg). Acalabrutinib Capsules are indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Maharashtra govt approves M&M proposal to set up Rs 10k-cr EV plant in Pune

Mahindra & Mahindra (M&M) said the Maharashtra government has approved its proposal to set up a Rs 10,000-crore electric vehicle plant in Pune under the state's industrial promotion scheme for EVs. The two sides signed an agreement to this effect at the World Economic Forum in Davos on Wednesday. The company, through its subsidiary, will make this investment over a period of 7-8 years for setting up the manufacturing facility, development and production of its upcoming Born Electric Vehicles (BEVs). The company has received this approval from the Maharashtra government for setting up its EV manufacturing plant in Pune, and investing in what has been its 'home' state for over 70 years, said Rajesh Jejurikar, Executive Director for auto and farm sector at Mahindra & Mahindra Ltd.

December retail sales jump 16% from pre-Covid levels

The Retailers Association of India (RAI) conducted the 35th edition of the Retail Business Survey, according to which the retail sales in December 2022 grew 16 per cent as against the sales recorded during December 2019 or the pre-pandemic period. December, retail businesses across regions indicated a jump in sales as compared to pre-pandemic levels with east India signaling a growth of 20 per cent, while retailers in south India and west India reporting a growth of 18 per cent and 16 per cent, respectively, followed by 10 per cent growth in North India.



CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.						
Company	Details					
Shradha Infraprojects Ltd	Cash dividend of INR2 effective 20-01-2023					
DCM Financial Services Ltd	Corporate meeting effective 20-01-2023					
Filtron Engineers Ltd	Corporate meeting effective 20-01-2023					
Goldstar Power Ltd/India	Stock dividend of INR1.8 effective 20-01-2023					
Deep Diamond India Ltd	10 for 1 stock split effective 20-01-2023					
Goldstar Power Ltd/India	10 for 1 stock split effective 20-01-2023					
Shradha Infraprojects Ltd	2 for 1 stock split effective 20-01-2023					

Domestic Events

India Foreign Exchange Reserve for January 13, 2023.

Global Events

- The U.S. Existing Home Sales for December 2022.
- Japan Inflation for December 2022.

Source of News: The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.



Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document



to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independednt views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.



SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or comanaging public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.nseindi

SMIFS submit's that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (https://www.smifs.com/)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com